The oncology field has witnessed a groundbreaking advancement with the introduction of EPKINLY (epcoritamab), a first-in-class CD20xCD3 bispecific antibody that has revolutionized the treatment landscape for patients with diffuse large B-cell lymphoma (DLBCL). This innovative therapeutic approach represents a paradigm shift from conventional chemotherapy-based treatments to precision immunotherapy. The Science Behind EPKINLY’s Dual-Targeting Mechanism EPKINLY… Read.